Navigation Links
Quark Pharmaceuticals Presents at Asia TIDES Conference
Date:3/9/2009

i>.

Dr. Thompson commented, "Quark has kept pace or out-performed on every major benchmark by which RNAi therapeutics companies are measured. With QPI-1002, Quark became the first to administer a siRNA drug systemically in humans. Our proprietary structures have supplied us with freedom to operate in the siRNA IP space and Quark is currently developing a pipeline of novel synthetic siRNA compositions starting with QPI-1007."

Dr. Thompson has been at the forefront of siRNA development for several years. Prior to joining Quark, he was Director of Research and Development at Genta, and previously was Director of Biology Research at Ribozyme Pharmaceuticals, which was acquired by Merck after changing its name to Sirna Therapeutics.

About Quark Pharmaceuticals, Inc.

Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical company engaged in discovering and developing novel RNAi-based therapeutics. Quark has a fully integrated drug development platform that spans therapeutic target identification to drug development. Quark's RNAi technology includes novel siRNA structures and chemistry providing Quark with freedom to operate in the siRNA intellectual property arena, as well as the ability for non-invasive delivery of siRNA to other target tissues including the eye, ear, lung, spinal cord and brain.

PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a synthetic, chemically modified siRNA designed to inhibit the expression of the gene RTP801 discovered by Quark through the gene discovery platform BiFAR. PF-4523655 is licensed to Pfizer. In addition, Quark's current clinical pipeline includes QPI-1002, the first systemically administered siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these
'/>"/>

SOURCE Quark Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
3. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss
6. Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans
7. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
8. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
9. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
10. Quark Pharmaceuticals Announces Publication of Study on Use of siRNA against Proprietary Target for Inhibiting Tumor Growth and Sensitization of Cancer Cells to Chemotherapy
11. Quark Pharmaceuticals Announces Dosing of the First Patient in Phase I/II Clinical Trial for Systemically Delivered siRNA Drug Candidate for Delayed Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... SANTA MONICA, Calif., Dec. 15 Dakim, Inc. ... ,Give Thanks for Loved Ones, Brain Health Contest, designed ... the symptoms of dementia and Alzheimer,s disease. All five ... first product designed specifically to help seniors preserve their ... its kind in senior living communities across the country. ...
(Date:12/15/2009)... 15 A Harvard medical expert internationally recognized ... the PGA Tour,s decision last month to suspend ... diagnosed him as having the medical condition ... condition is "unreasonable, unfair and discriminatory." ,, ... normal testosterone levels, often referred to informally as ...
(Date:12/15/2009)... Today,s New York Times ... Spurs Division," illustrates an internal renal community reimbursement ... to be deprived of their life-saving immunosuppressive medications ... As Congress is poised to approve this urgent ... transplant kidney recipients, behind-the-scenes debate continues within the ...
Breaking Medicine Technology:5 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 2Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 3Harvard Medical Expert Criticizes PGA Tour, Calls Decision to Suspend Doug Barron for Doping 'Unreasonable, Unfair and Discriminatory' 4AST Concerned That Kidney Transplant Patients May Suffer Politics As Usual in Capitol Hill Health Care Reform Debate 2Hip Arthroscopy Procedures to Soar Through 2013 51045 1Hip Arthroscopy Procedures to Soar Through 2013 51045 2DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 1DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 2DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 3DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 4DOR BioPharma Announces Issuance of European Patent for its LPM 28TM 29 Oral Drug Delivery Technology 12934 5Funxional successfully completes initial clinical trial of FX125L an anti inflammatory drug with a novel mechanism of action 9159 1Funxional successfully completes initial clinical trial of FX125L an anti inflammatory drug with a novel mechanism of action 9159 2
(Date:12/16/2009)... Reinertsen has run marathons, competed in triathalons and appeared on ... News) -- Sarah Reinertsen likes to think of herself as ... two-legged world is how the 34-year-old triathlete likes to describe ... find her speaking to packed school auditoriums or posing nude ... on the cover of the latest ESPN Body ...
(Date:12/16/2009)... - TSO3 Inc. ("TSO3") (TSX: TOS) and 3M ... reached for 3M to be the exclusive supplier ... partnership with TSO3, an innovator in low temperature ... through the use of ozone, will include new ... global sales channel. This agreement, combined with recent ...
(Date:12/16/2009)... time it takes to obtain a bachelor degree, an individual ... , ... (Vocus) December 16, 2009 ... Report Card on Higher Education" by the National Center for ... outpaced price increases in other sectors of the economy.”¹ Since ...
(Date:12/16/2009)... approaching and what would be the perfect gift to give that ... Celebrity Beauty Engineer® and Licensed Esthetician Mary Schook introduces exceptional beauty ... feel their best! , ... (PRWEB) December 16, 2009 ... does a person get that special woman who has everything? Why ...
(Date:12/15/2009)... 15 The failure of the U.S. ... cut costs, much less the more effective direct ... latest example of how big industry controls the ... proposed drug amendment by Senator Dorgan (D-ND) was ... campaign pledge to allow Medicare to directly negotiate ...
Breaking Medicine News(10 mins):Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 2Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 3Health News:TSO3 and 3M agree to global channel partnership - 3M to begin rollout in sequential markets as regulatory clearances are received 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 2Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 3Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 4Health News:Career in Eye Care Practical Compared to Rising Tuition Costs 5Health News:New Online Beauty Store Suggests Stem Cells for the Woman Who Has Everything 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 2Health News:Failure of Drug Importation Amendment in U.S. Senate is Latest Show of Industry's Controlling Hand in Health Reform Debate, According to Consumer Watchdog 3
... published in BJOG: An International Journal of Obstetrics and ... praevia and placental abruption during the subsequent pregnancies ... ,Placental praevia is defined as the implantation ... of the cervix. Placenta abruption is the premature separation ...
... Nutrition Coalition on Tuesday launched a campaign to encourage ... . The obesity rate for U.S. Hispanics increased from ... are more likely to be obese and two times ... not Hispanic, the AP/Star reports. ,LNC's ...
... Bereaved families of firefighters who lost their lives to work- ... relief at last. Ontarios new labor laws state that they ... in order to qualify for compensation due the dead workers ... identify eight types of cancer that will be presumed to ...
... administration in the US. A Defence Department panel has ... posing a serious challenge on two fronts. ,One, ... problems. Second at the current level of staffing and funds, ... those affected necessary statement. ,In a damning revelation, ...
... peels, facelifts, there is no dearth of "anti-aging" products and ... and more American women go for them not just to ... order to be competitive enough in the market place, many ... of the botulinum toxin. The toxin blocks the transmission of ...
... schoolchildren, available data says. The question is whether early exposure ... of scientists from the King's College London and doctors ... seven-year study and hope to rope in 480 children in ... between four and 11 months and already have eczema or ...
Other Medicine News:Health News:Placental Problems in Women Linked With Caesarean Section 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 2Health News:Ontario Grants Fast-Track Compensation Rights for Work-Related Illnesses 3Health News:One Third of US Troops Suffer from Mental Health Problems 2Health News:One Third of US Troops Suffer from Mental Health Problems 3Health News:More and More American Women Go for Facelifts to Get Jobs 2Health News:UK Scientists to Undertake Seven Year Study of Peanut Allergy 2
The ABI PRISM 3100 Genetic Analyzer, a multi-color fluorescence-based DNA analysis system with 16 capillaries operating in parallel, offers high-quality data and efficient sample processing for the b...
... latest 3-part differential analyzer based on the ... the CELL-DYN line. Offering 18 parameters and ... CELL-DYN 1800 meets the needs to today's ... than its predecessors and fits under standard ...
... QC Manager Point-of-Care Data Management System provides ... Glucose Testing System and the Precision PCx. ... automated way to collect, analyze, and report ... It provides an essential laboratory tool for ...
... Test is a color immunochromatographic assay using ... labeled color particles coated at two separate ... greater sensitivity than the conventional single label ... procedure, a throat swab is subjected to ...
Medicine Products: